Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A06AX04

Constella(linaclotide)

Irritable Bowel Syndrome

Marketing Authorisation Holder: AbbVie Deutschland GmbH & Co. KG

EMA Authorisation: 26/11/2012

INN: linaclotide

Indication

Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Constella — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.